Kindred Biosciences Inc (NASDAQ: KIN), a United States-based biopharmaceutical company, reported on Wednesday its financial results for the six months ended 30 June 2020.
The company reported net income of USD1.3m or USD0.03 per share (diluted) in the six months ended 30 June 2020 compared to a net loss of USD30.4m, or USD0.79 per share, in the year-ago period.
The firm posted net revenues of USD40.2m in the six months ended 30 June 2020 compared to USD1.8m in the year-ago period.
'We are pleased with the progress on our pipeline of late-stage biologics,' said KindredBio's chief executive officer, Richard Chin, MD. 'The commencement of the first parvovirus pivotal study is a key milestone for this program, and we look forward to the upcoming initiation of the tirnovetmab (IL-31 antibody) pivotal study.'
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo